Nevertheless, other mechanisms might govern CDCP1 expression in TNBC primary tumors without such gains, such as those in tumor hypoxia in renal cancer cells [34] and hepatocellular carcinoma [35], the EGF/EGFR pathways in ovarian models [36], BMP4 in pancreatic cells [37], and unidentified molecules in the tumor microenvironment of primary TNBCs, as suggested by WHF treatment. This evidence concerns the gene EGF and hepatocellular carcinoma.